Janus Mesoporous Silica Nanoparticles for Dual Targeting of Tumor Cells and Mitochondria

2017 ◽  
Vol 9 (32) ◽  
pp. 26697-26706 ◽  
Author(s):  
Victoria López ◽  
Maria Rocío Villegas ◽  
Verónica Rodríguez ◽  
Gonzalo Villaverde ◽  
Daniel Lozano ◽  
...  
Keyword(s):  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Tumor Cells ◽  
Mesoporous Silica Nanoparticles ◽  
Dual Targeting

scholarly journals Gene-Directed Enzyme Prodrug Therapy by Dendrimer-Like Mesoporous Silica Nanoparticles against Tumor Cells

Nanomaterials ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 1298
Author(s):  
Vicente Candela-Noguera ◽  
Gema Vivo-Llorca ◽  
Borja Díaz de Greñu ◽  
María Alfonso ◽  
Elena Aznar ◽  
...  
Keyword(s):  
Cell Death ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Tumor Cells ◽  
Mesoporous Silica Nanoparticles ◽  
Combined Treatment ◽  
Bond Rupture ◽  
Enzyme Prodrug Therapy ◽  
Bacterial Gene ◽  
Reducing Environment

We report herein a gene-directed enzyme prodrug therapy (GDEPT) system using gated mesoporous silica nanoparticles (MSNs) in an attempt to combine the reduction of side effects characteristic of GDEPT with improved pharmacokinetics promoted by gated MSNs. The system consists of the transfection of cancer cells with a plasmid controlled by the cytomegalovirus promoter, which promotes β-galactosidase (β-gal) expression from the bacterial gene lacZ (CMV-lacZ). Moreover, dendrimer-like mesoporous silica nanoparticles (DMSNs) are loaded with the prodrug doxorubicin modified with a galactose unit through a self-immolative group (DOXO-Gal) and modified with a disulfide-containing polyethyleneglycol gatekeeper. Once in tumor cells, the reducing environment induces disulfide bond rupture in the gatekeeper with the subsequent DOXO-Gal delivery, which is enzymatically converted by β-gal into the cytotoxic doxorubicin drug, causing cell death. The combined treatment of the pair enzyme/DMSNs-prodrug are more effective in killing cells than the free prodrug DOXO-Gal alone in cells transfected with β-gal.

scholarly journals Multiple-Responsive Mesoporous Silica Nanoparticles for Highly Accurate Drugs Delivery to Tumor Cells

ACS Omega ◽  
2018 ◽  
Vol 3 (4) ◽  
pp. 4306-4315 ◽  
Author(s):  
Ronghua Jin ◽  
Zhongning Liu ◽  
Yongkang Bai ◽  
Yongsheng Zhou ◽  
Xin Chen
Keyword(s):  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Tumor Cells ◽  
Mesoporous Silica Nanoparticles

A novel nanomissile targeting two biomarkers and accurately bombing CTCs with doxorubicin

Nanoscale ◽  
2017 ◽  
Vol 9 (17) ◽  
pp. 5624-5640 ◽  
Author(s):  
Yu Gao ◽  
Xiaodong Xie ◽  
Fengqiao Li ◽  
Yusheng Lu ◽  
Tao Li ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Mesoporous Silica ◽  
Cancer Survivors ◽  
Silica Nanoparticles ◽  
Tumor Cells ◽  
Cancer Metastasis ◽  
Low Dose ◽  
Mesoporous Silica Nanoparticles ◽  
Primary Colorectal Cancer ◽  
Colorectal Cancer Metastasis

Rare circulating tumor cells (CTCs) cause >50% of primary colorectal cancer survivors to develop deadly metastasis at 3–5 years after surgery; current bi-aptamer-targeted mesoporous silica nanoparticles loaded with doxorubicin were developed for effective low dose colorectal cancer metastasis chemoprevention.

scholarly journals Galactosylated Chitosan-Functionalized Mesoporous Silica Nanoparticle Loading by Calcium Leucovorin for Colon Cancer Cell-Targeted Drug Delivery

Molecules ◽  
2018 ◽  
Vol 23 (12) ◽  
pp. 3082 ◽  
Author(s):  
Wei Liu ◽  
Fan Wang ◽  
Yongchao Zhu ◽  
Xue Li ◽  
Xiaojing Liu ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Colon Cancer ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Tumor Cells ◽  
Targeted Drug Delivery ◽  
Mesoporous Silica Nanoparticles ◽  
Drug Loading ◽  
Targeted Drug ◽  
Galactosylated Chitosan

Targeted drug delivery to colon cancer cells can significantly improve the efficiency of treatment. We firstly synthesized carboxyl-modified mesoporous silica nanoparticles (MSN–COOH) via two-step synthesis, and then developed calcium leucovorin (LV)-loaded carboxyl-modified mesoporous silica nanoparticles based on galactosylated chitosan (GC), which are galectin receptor-mediated materials for colon-specific drug delivery systems. Both unmodified and functionalized nanoparticles were characterized by scanning electron microscopy (SEM), transmission electron microscope (TEM), X-ray diffraction (XRD), Fourier transform infrared (FT-IR), nitrogen sorption, and dynamic light scattering (DLS). Drug release properties and drug loading capacity were determined by ultraviolet spectrophotometry (UV). LV@MSN–COOH/GC had a high LV loading and a drug loading of 18.07%. In vitro, its release, mainly by diffusion, was sustained release. Cell experiments showed that in SW620 cells with the galectin receptor, the LV@MSN–COOH/GC metabolized into methyl tetrahydrofolic acid (MTHF) and 5-fluorouracil (5-FU)@MSN–NH2/GC metabolized into FdUMP in vivo. MTHF and 5-fluoro-2′-deoxyuridine 5′-monophosphate (FdUMP) had combined inhibition and significantly downregulated the expression of thymidylate synthase (TS). Fluorescence microscopy and flow cytometry experiments show that MSN–COOH/GC has tumor cell targeting, which specifically recognizes and binds to the galectin receptor in tumor cells. The results show that the nano-dosing system based on GC can increase the concentrations of LV and 5-FU tumor cells and enhance their combined effect against colon cancer.

Dual responsive mesoporous silica nanoparticles for targeted co-delivery of hydrophobic and hydrophilic anticancer drugs to tumor cells

2016 ◽  
Vol 4 (25) ◽  
pp. 4382-4388 ◽  
Author(s):  
Xin Chen ◽  
Zhongning Liu
Keyword(s):  
Drug Resistance ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Cancer Cells ◽  
Tumor Cells ◽  
Anticancer Drugs ◽  
Tumor Targeting ◽  
Mesoporous Silica Nanoparticles ◽  
Dual Responsive

Dual responsive mesoporous silica nanoparticles integrating stepwise tumor targeting and co-delivery of multiple anticancer drugs were developed to attenuate the drug resistance of cancer cells.

Sign in / Sign up

Export Citation Format

Share Document